In the anticancer efficacy study of medicarpin on U251 and U87 glioblastoma cells, it was found that medicarpin increased apoptosis in cancer cells by increasing BAX, CYCS and CASP3 gene levels and also decreased Bcl‐2 levels [52]. This evidence concerns the gene BCL2 and cancer.